Citi Sees Positive Catalysts for Telix Pharmaceuticals
Dow Jones
Jul 15
2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. "We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus," analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at "buy, high-risk." (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
July 14, 2026 19:06 ET (23:06 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.